Evidence map›Paper›PMID 29788338›Full record

ReviewInflammatory bowel diseases2018

Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease.

Amy Hemperly, William J Sandborn, Niels Vande Casteele

Open access · bronzeAbstract readReviewVideo-Audio Media
In one paragraph

Review in Inflammatory bowel diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022
    Review
  12. Article
  13. Article
  14. Review
  15. Cannabidiol Isolated FromFrontiers in pharmacology · 2021
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amy HemperlyDepartment of Pediatric Gastroenterology, La Jolla, California.
William J SandbornDepartment of Medicine, Division of Gastroenterology, University of California San Diego, La Jolla, California.
Niels Vande CasteeleDepartment of Pediatric Gastroenterology, La Jolla, California.
University of California, San Diego · US

Funding

Developing Pediatric Clinical Pharmacologists for the Advancement of TherapeuticsT32HD087978 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR, TREMOULET, ADRIANA H · 2016 to 2025
$1.5M
NICHD NIH HHS T32 HD087978
6 · The paper itself

Abstract

This review describes the clinical pharmacology of the major drugs used for the treatment of patients with inflammatory bowel disease (IBD). Pharmacokinetics, drug metabolism, mechanism of action, efficacy, and safety profile are discussed. Some small molecules were developed to act systemically (eg, ozanimod) or locally (eg, aminosalicylates) and thus have disparate pharmacokinetic properties. In addition, locally acting compounds have been optimized to mitigate systemic exposure-eg, budesonide, which undergoes extensive first-pass metabolism-thereby reducing systemic bioavailability and side effects. Other small molecules such as thiopurines are precursors of their active metabolites and differences in genotype or phenotype of metabolizing enzymes may affect efficacy and safety, requiring therapeutic drug monitoring (TDM). Monoclonal antibodies (MAs) are large molecules administered parenterally, and their pharmacokinetics may be influenced not only by the general immunoglobulin (Ig) G metabolism and recycling pathways but also by antigen properties such as antigen distribution and antigen concentration. In addition, antibody structure, host factors, concurrent medications, and immunogenicity may contribute to the substantial inter- and intrapatient variability in drug exposure and response observed for MAs. Current guidelines recommend reactive TDM of tumor necrosis factor antagonists at the time of loss of response. Evidence for proactive TDM and for the role of TDM for biologics with a different mechanism of action is emerging. Although small molecules offer potential benefits over biologics with oral administration and lack of immunogenicity, there may be risk for more systemic side effects due to off-target binding. Understanding drug metabolism, pharmacokinetic characteristics, and mechanism of action are important in selecting the right drug at the right time at the right dose for patients with IBD.10.1093/ibd/izy189_video1izy189.video15786062223001.

Indexed as

AdultAntibodies, Monoclonal, HumanizedBiological ProductsChildDrug MonitoringGastrointestinal AgentsHumansInflammatory Bowel DiseasesJanus Kinase InhibitorsRandomized Controlled Trials as TopicTumor Necrosis Factor-alphaAntibodies, Monoclonal, HumanizedBiological ProductsGastrointestinal AgentsJanus Kinase InhibitorsTumor Necrosis Factor-alpha

Identifiers

PMID29788338
PMCPMC11187819
OpenAlexW2804664806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.